

1 **Relationships of Prescription Opioid Sales to Opiate Treatment Admissions and Overdose**
2 **Deaths: A Reanalysis of Relationships -- United States 2010-2019**

3

4 Larry Aubry and B. Thomas Carr

5 Corresponding Author:

6 B. Thomas Carr

7 Carr Consulting

8 1215 Washington Avenue

9 Suite 201

10 Wilmette, IL 60091 USA

11 Email: Tom.Carr@CarrConsulting.net

12

13 **Relationships of Prescription Opioid Sales to Opiate Treatment Admissions and Overdose**
14 **Deaths: A Reanalysis of Relationships – United States 2010-2019**

15 Larry Aubry and B. Thomas Carr

16

17 **ABSTRACT**

18

19 **Background:** In 2016, the United States Centers for Disease Control and Prevention
20 (CDC) issued “CDC Guideline for Prescribing Opioids for Chronic Pain”. The guideline used
21 data from 1999 to 2010 that related Opioid Sales to Opiate Treatment Admissions (a measure
22 of drug addiction rates) Opioid Deaths. The CDC’s analysis indicated that opioid prescriptions
23 are directly correlated¹⁻⁸ with drug addiction and overdose mortality outcomes. As a result,
24 prescription opioid sales have been curtailed, making it difficult for sufferers of severe chronic
25 pain to access an effective treatment option. In this paper, the relationships between opioid
26 sales, drug addiction, and opioid deaths are reexamined using data from 2010 to 2019.

27 **Methods:** Linear regression models were fit to each response separately. Opioid sales
28 (measured as MME per capita) was the independent variable. Total overdose deaths (TOD),
29 any opioid overdose deaths (AOD), prescription opioid overdose deaths (POD) and opiate
30 treatment admissions (OTA) were the dependent, response variables. The models were
31 assessed using three criteria: the statistical significance of the model (Overall P-Value), the
32 quality of the fit (R^2), and the sign of the slope coefficient.

33 **Results:** The analyses revealed that the direct correlations (significant, positive slopes)
34 reported by the CDC based on data from 1999 to 2010 no longer exist based on data from 2010
35 to 2019. The relationships either have reversed (i.e., significant negative slopes) or are non-
36 existent (no significant model).

37 **Conclusions:** The basis for the CDC guideline no longer holds. The guideline should
38 be updated or annulled based on the current relationships that have existed for a decade. This
39 is especially relevant for people suffering from severe, chronic pain, whose access to
40 prescription opioids has been severely curtailed under the current guideline and to ensure that
41 government resources are directed to an effective approach to reducing overdose deaths.

42

43 **BACKGROUND AND RATIONALE**

44

45 In 2015, the U.S. Department of Health and Human Services (HHS) declared “There is a
46 clear correlation between opioid prescribing rates and overdose death rates in the United

47 States.”⁹ Direct correlations that existed between Total Overdose Deaths (TOD), Any Opioid
48 Deaths (AOD), Prescription Opioid Deaths (POD), Opiate Treatment Admissions (OTA) and
49 prescription opioid sales (POS) from 1999-2010 (see Figure 1) led the CDC to conclude that
50 prescribed opioids are the determinant for overdose deaths and opiate/opioid treatment
51 admissions.¹⁻⁸ Since the 2016 “CDC Guideline for Prescribing Opioids for Chronic Pain”
52 (guideline), cutting prescription opioid sales has been CDC’s, DEA’s, legislative policy makers’,
53 and practitioners’ solution to cut overdose deaths and opiate treatment admissions.¹⁰⁻¹²

54

55 *** Place Figure 1 Approximately Here ***

56

57 The impact of the CDC guideline has been systemic. Long term opioid therapy patients are not
58 accepted as new patients by over 40% of primary pain clinics.¹² Projected cuts to opioid Rx
59 MME per capita will result in 2020 values falling close to levels prescribed in 2000 of 298¹³ while
60 the over 55 population has increased by 40 million. The American Medical Association (AMA)
61 reports “the CDC Guideline has harmed patients”¹⁴, “72% of pain medicine specialists said that
62 they—or their patients—have been required to reduce the quantity or dose of medication they
63 have prescribed”¹⁴ as a result of the guideline.

64 “Almost 18 million Americans are currently taking long-term prescription opioids”¹⁵ to
65 treat chronic pain. A “Health and Human Services Pain Management Best Practices Inter-
66 Agency Task Force has determined that tens of millions of Americans rely on legal prescription
67 opioids to treat acute or severe chronic pain, including pain arising from cancer as well as
68 terminal or degenerative illnesses. The Food and Drug Administration (FDA) long ago approved
69 opioid medications for these purposes, and doctors throughout the country lawfully prescribe
70 them.”¹⁶ 92% of physicians and patients believe that opioids reduce pain and 57% report better
71 quality of life.¹⁷

72

73 With drug overdose deaths “growing, inexorably and exponentially, for four decades”¹⁸ to
74 a record 93,000 in 2020; FY2019 federal funding to combat the opioid crisis increasing to a
75 record \$7.6 billion¹⁹ and “drug overdoses are now costing the United States approximately \$1
76 trillion annually”,²⁰ it is critical that public health policy guidance not be based on out-of-date
77 and/or misleading information.

78

79 The present paper updates correlations between POS to OTA, POD, AOD and TOD
80 from 2010 to 2019 and shows that the direct relationships that existed from 1999 to 2010 are no

81 longer present -- in fact, in some instances the relationships have reversed. Consequently, we
82 find that continuing the policies of cutting prescription opioid sales to reduce TOD, AOD, POD,
83 and OTA is unfounded.

84

85 **METHODS:**

86

87 **DESCRIPTION OF DATA SOURCES:**

88

89 **Data Limitations:** The authors acknowledge that the data reported by CDC and other
90 sources necessarily contains inaccuracies. It is widely understood that it is impossible to
91 ascertain the specific cause of an overdose death in all cases. This may be due, for example, to
92 poly drug use with alcohol, and an inability to reliably determine the source of opioids detected
93 in postmortem blood toxicity screens (e.g., prescription vs. illicit), among other confounding
94 issues.^{21,22} However, the authors have employed the same data sources that CDC guideline
95 appears to be based upon. As such, the results of analyses presented here are at least as
96 reliable as what the CDC would be able to obtain from their own analyses, if they chose to
97 undertake them. Thus, the following sources have been applied.

98

99 **Drug Overdose Deaths (National); Total Overdose Deaths, Any Opioid Overdose**
100 **Deaths and Prescription Opioid Overdose Deaths**²³: 1999-2019 data accessed from
101 Drugabuse.gov., Published 2021. Accessed January 10, 2021 from
102 https://www.drugabuse.gov/sites/default/files/Overdose_data_1999-2019.xlsx

103

104 **Opioid Overdose Death Crude Rates (U.S. States)**²⁴: 1999-2019 data accessed from
105 CDC, National Center for Health Statistics. Underlying Cause of Death, 1999-2019 were
106 sourced from CDC WONDER Online Database, released in 2020. Data are from the Multiple
107 Cause of Death Files, 1999-2019, as compiled from data provided by 57 vital statistics
108 jurisdictions through the Vital Statistics Cooperative Program. Identified using underlying cause-
109 of-death codes X40–X44, X60–X64, X85, and Y10–Y14. Accessed Feb 7, 2021, 12:01:39 PM
110 from <http://wonder.cdc.gov/ucd-icd10.html>

111

112 **Opiate/Opioid Treatment Admissions (National)**²⁵: 2006-2008 data accessed
113 from Substance Abuse and Mental Health Services Administration, Center for Behavioral Health
114 Statistics and Quality, "Treatment Episode Data Set (TEDS): 2000-2010". National Admissions

115 to Substance Abuse Treatment Services. DASIS Series S-61, HHS Publication No. (SMA) 12-
116 4701. Rockville, MD: Substance Abuse and Mental Health Services Administration
117 (samhsa.gov), 2012. p.43. Accessed April 18, 2021 from [Treatment Episode Data Set \(TEDS\)](#)
118 [2000 - 2010 \(samhsa.gov\)](#)

119
120 **Opiate/Opioid Treatment Admissions (National)²⁶:** 2008-2018 data accessed from
121 Substance Abuse and Mental Health Services Administration, Center for Behavioral Health
122 Statistics and Quality, “Treatment Episode Data Set (TEDS): 2018.”
123 Admissions to and Discharges from Publicly Funded Substance Use Treatment. Rockville, MD:
124 2018 TEDS Annual Report. Substance Abuse and Mental Health Services Administration
125 (samhsa.gov), 2020. Table 1.1a. Accessed April 18, 2021 from
126 [https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html#](https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html#PSU.2018TEDSAnnualReport(samhsa.gov))
127 [PSU. 2018 TEDS Annual Report \(samhsa.gov\)](#)

128
129 **Opioid Prescribing; MME per Capita (National)²⁷:** 2006-2013 data accessed from
130 CDC,” Annual Surveillance Report of Drug-Related Risks and Outcomes — United States
131 Surveillance Special Report”.2019 CDC, U.S. Department of Health and Human Services.
132 Published November 1, 2019. p.115. Accessed January 10, 2021 from
133 <https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf>

134
135 **Opioid Prescribing; MME per Capita (National)²⁸:** 2014-2018 data accessed from
136 Statista,” Annual morphine milligram equivalents (MME) dispensed per capita in the U.S. from
137 2014 to 2018”, MME per capita U.S. 2014-2018. Statista. May 28, 2021. Accessed July 8, 2021
138 from <https://www.statista.com/statistics/753284/number-of-mme-dispensed-per-capita-in-us/>.

139
140 **Opioid Prescribing; MME per Capita (National)²⁹:** 2019 data accessed from The
141 IQVIA Institute, “Prescription Opioid Trends in the United States”, Institute Report, Dec 16,
142 2020. p.4. Accessed January 10, 2021 from [https://www.iqvia.com/insights/the-iqvia-](https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states)
143 [institute/reports/prescription-opioid-trends-in-the-united-states](#).

144
145 **Opioid Prescribing; Opioid Dispensing Rates per 100 (U.S. States)³⁰:**
146 2006-2019 data accessed from CDC, “U.S. Opioid Dispensing Rate Maps, Drug Overdose”,
147 CDC Injury Center. Accessed February 9, 2021 from <https://www.cdc.gov/drugoverdose/rxrate->

148 [maps/index.html](#)

149

150 **Opioid Sales kg/10,000 (National):** For the period from 2006 through 2018/2019, these
151 data were not known to be publicly available. We instead examined Opioid Prescribing by
152 separately computing MME per Capita.

153

154 **STATISTICAL METHODOLOGY:**

155

156 **Objective 1: Evaluate MME per Capita as a legitimate alternative measure of**
157 **Annual Prescription Opioid Sales:** The CDC used Annual Prescription Opioid Sales to
158 support their current guideline (Figure 1). Data on Annual Prescription Opioid Sales are not
159 readily available since 2010. However, MME per Capita data are available from 2006 to 2019
160 and offer a reasonable surrogate. Annual Sales data from the CDC chart were visually extracted
161 and correlated with MME per Capita data, using simple linear regression analysis. The goal of
162 the analysis was to evaluate MME per Capita as a legitimate alternative measure of Annual
163 Prescription Opioid Sales.

164

165 **Objective 2: Assess the strength and nature of the relationships between total**
166 **overdose deaths (TOD), any opioid overdose deaths (AOD), prescription opioid overdose**
167 **deaths (POD) and opiate treatment admissions (OTA) and Opioid Sales/MME per Capita:**
168 Consistent with the methods used by the CDC, simple linear regression models were fit to the
169 data. Separate models were fit to each of the four dependent variables (TOD, AOD, POD, and
170 OTA) using Annual Opioid Sales (i.e., MME per Capita) as the independent variable. Two
171 models were fit to each dependent variable. One model covered the years presented in the
172 original CDC chart (for which MME per Capita data were available) (2006-2010) and the second
173 model covered the years since the published CDC chart (2010-2019).

174

175 For both objectives, the strength and nature of relationships in all the regression models were
176 assessed using three criteria:

177

178 1) significance of the regression model (overall P-Value),

179

180 2) the quality of the model's fit (R^2), and

181

182 3) the sign of the linear slope coefficient (+ or -).

183

184 All models were fit using PROC REG from SAS/STAT software Version 9.4.

185

186 **RESULTS AND DISCUSSION**

187

188 Data from CDC's original chart was reconstructed using graphical analysis. The
189 reconstructed Annual Prescription Opioid Sales values from the original CDC chart are highly
190 correlated with publicly available MME per Capita values ($R^2 = 94\%$), which are available for
191 more recent years than the sales data used by the CDC. MME per Capita is thus used in place
192 of Annual Prescription Opioid Sales for all subsequent analyses.

193

194 For the years covered in the CDC's original chart (for which MME per Capita data are
195 available, i.e., 2006-2010), the CDC's claim of positive/direct relationships between TOD, AOD,
196 POD, and OTA and Annual Prescription Opioid Sales (i.e., MME per Capita) were validated
197 ($91\% < R^2 < 97\%$), with statistically significant, positive slopes.

198

199 For more recent years (i.e., 2010-2019), however, the CDC's assertion of continued
200 direct relationships is not valid. The relationships between TOD, AOD, POD, and OTA and
201 Annual Prescription Opioid Sales (i.e., MME per Capita) are either non-existent or significantly
202 negative/inverse (Figures 2 and 3).

203

204 *** Place Figure 2 Approximately Here ***

205

206 *** Place Figure 3 Approximately Here ***

207

208 National trends since 2010 are paralleled in a strong majority of states. Between 2010
209 and 2019 inclusive, there was a statistically significant negative correlation (95% confidence
210 level) between AOD and Annual Prescription Opioid Sales in 40 states, with significant positive
211 correlations occurring in only 2 states. Eight (8) states did not exhibit a significant (95%
212 confidence level) relationship between overdose deaths and prescription opioid sales during the
213 2010-2019 time period.

214

215 Results for all regression models are presented in Table 1.

216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249

*** Place Table 1 Approximately Here ***

CONCLUSIONS:

Starting in 2010 opioid MME per Capita (POS) does not have a “clear correlation”⁹ or move “in parallel”³ or “in lockstep”² with OTA, POD, AOD or TOD. The relationship changed from direct to inverse.

From a peak in 2010 to 2019, POS decreased by over 50%. If POS were the root cause, correlated to and resulted in “parallel” or “lockstep” movements in POD, AOD, OTA, and TOD, then the result should have been an equivalent percentage reduction in these metrics. From 2010 to 2019, POD should have been 6,800 in 2019 instead of ending the decade flat at 14,139; AOD should have been 9,900 instead of increasing by 2.5x to 49,860; OTA should have been less than 210,000 in 2018 instead of increasing by 1.6x to 650,212 and TOD should be 17,900 instead of doubling to 70,630.

Data from the National Health Interview Survey (NHIS) demonstrate that between 2011 to 2016, while MME per capita declined by 21.8%, the amount of pain reported by Americans significantly increased. Incidence of high impact chronic pain increased by 84.9%, from 4.8 percent (10.6 million people, 1 in 20)³¹ to 8.0% of U.S. adults (19.6 million, 1 in 12.5)³². Incidence of patients afflicted with chronic pain increased by 67.2% from 13.6 percent (29.9 million, 1 in 7.4)³¹ to 20.4% (50.0 million, 1 in 5)³² of the U.S. adult population.

In light of the evidence presented in this paper, it should be recognized that the basis for the 2016 guideline is no longer valid. The guideline and associated content should be updated or annulled based on the current relationships that have existed for a decade, to eliminate the unnecessary suffering of individuals with chronic pain and to avoid the wasteful and ineffective spending patterns the government is executing based on the out-of-date guideline.

Source of Funding: None.

Author Disclosures: The authors report no relationship or financial interest with any entity that would pose a conflict of interest concerning the subject matter of this paper.

250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283

References:

1. CDC Press Releases. (2016, January 1). CDC.
<https://www.cdc.gov/media/releases/2016/p0315-prescribing-opioids-guidelines.html>
2. NCIPC Board of Scientific Counselors. “Draft Meeting Minutes” Department of Health and Human Services Public Health Service Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control (NCIPC) Eighteenth Meeting: Thursday, January 28, 2016: p.9.
https://www.cdc.gov/injury/pdfs/bsc/NCIPC_BSC_01_28_2016_Minutes_Final_3_15_2016.pdf.
3. CDC Guideline for Prescribing Opioids for Chronic Pain -United States, 2016 Morbidity and Mortality Weekly Report. (2016): p.2.
<https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf>
4. Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999--2008. Published 2019. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm>
5. Haegerich, T. (2018). The Opioid Overdose Epidemic in the United States NCIPC/CDC Research Priorities: p.34. https://www.cdc.gov/injury/pdfs/bsc/Opioid-Research-Priorities_BSCJune2018_Haegerich-a.pdf
6. Noonan, R. (2016). Understanding and Addressing the Opioid Crisis Nevada’s Prescription Drug Abuse Summit CDC PERSPECTIVE: p.8.
<https://dpbh.nv.gov/uploadedFiles/dpbh.nv.gov/content/Programs/ClinicalSAPTA/Meetings/5%20%20Rise%20of%20Heroin%20Rita%20Noonan.pdf>
7. Kolodny, A. (n.d.). Statement by:p.1,2.
<https://docs.house.gov/meetings/IF/IF14/20180228/106915/HHRG-115-IF14-Wstate-KolodnyA-20180228.pdf>
8. Bacon S. CDC’s Approach to Addressing the Opioid Overdose Epidemic.; 2016: p.7.
https://www.ncsl.org/portals/1/documents/health/InjuryMtg2016_SBacon.pdf

- 284 **9.** ASPE ISSUE BRIEF.; 2015. Accessed January 25, 2022: p.5.
285 https://aspe.hhs.gov/sites/default/files/migrated_legacy_files/56406/ib_OpioidInitiative.pdf
286
- 287 **10.** Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018). Opioid Crisis: No Easy Fix to Its
288 Social and Economic Determinants. *American journal of public health*, 108(2), 182–186.
289 <https://doi.org/10.2105/AJPH.2017.304187>
290
- 291 **11.** Chen, Q., Larochelle, M. R., Weaver, D. T., Lietz, A. P., Mueller, P. P., Mercaldo, S.,
292 Wakeman, S. E., Freedberg, K. A., Raphel, T. J., Knudsen, A. B., Pandharipande, P. V., &
293 Chhatwal, J. (2019). Prevention of Prescription Opioid Misuse and Projected Overdose Deaths
294 in the United States. *JAMA network open*, 2(2), e187621.
295 <https://doi.org/10.1001/jamanetworkopen.2018.7621>
296
- 297 **12.** Lagisetty, P., et al. Improving Access to Primary and Pain Care for Patients Taking
298 Opioids for Chronic Pain in Michigan: Recommendations from an Expert Panel. (2021): p.3.
299 <https://doi.org/10.7302/1699>
300
- 301 **13.** IQVIA, “Prescription Opioid Trends in the United States. Measuring and
302 understanding progress in the opioid crisis.” *Institute Report*. Dec 16, 2020. Accessed
303 August 26, 2021. [https://www.iqvia.com/en/insights/the-iqvia-](https://www.iqvia.com/en/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states)
304 [institute/reports/prescription-opioid-trends-in-the-united-states](https://www.iqvia.com/en/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states)
305
- 306 **14.** Majara, J.L. Docket No. CDC-2020-0029 Letter Dowell D, Dowell.; 2020. p.5,7
307 [https://searchlf.ama-](https://searchlf.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2F2020-6-16-Letter-to-Dowell-re-Opioid-Rx-Guideline.pdf)
308 [assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2F](https://searchlf.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2F2020-6-16-Letter-to-Dowell-re-Opioid-Rx-Guideline.pdf)
309 [LETTERS%2F2020-6-16-Letter-to-Dowell-re-Opioid-Rx-Guideline.pdf](https://searchlf.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2F2020-6-16-Letter-to-Dowell-re-Opioid-Rx-Guideline.pdf)
310
- 311 **15.** Beth D Darnall, PhD, David Juurlink, MD, PhD, FRCPC, FAACT, FACMT, Robert D
312 Kerns, PhD, Sean Mackey, MD, PhD, Brent Van Dorsten, PhD, Keith Humphreys, PhD, Julio A
313 Gonzalez-Sotomayor, MD, Andrea Furlan, MD, PhD, Adam J Gordon, MD, MPH, FACP,
314 DFASAM, CMRO, Debra B Gordon, RN, DNP, FAAN, Diane E Hoffman, JD, MS, Joel Katz,
315 PhD, CPsych, FCAHS, Stefan G Kertesz, MD, MSc, Sally Satel, MD, Richard A Lawhern, PhD,
316 Kate M Nicholson, JD, Rosemary C Polomano, PhD, RN, FAAN, Owen D Williamson,
317 FPPMANZCA, FRCSC Pain Medicine, Heath McAnally, MD, MSPH, Ming-Chih Kao, PhD, MD,

318 CIPS, Stephan Schug, MD, FANZCA, FFPMANZCA, EDPM, Robert Twillman, PhD, FACLP,
319 Terri A Lewis, PhD, NCC, Richard L Stieg, MD, MHS, Kate Lorig, DrPH, Theresa Mallick-Searle,
320 MS, APRN, Robert W West, PhD, Sarah Gray, PsyD, Steven R Ariens, RPh, PD, Jennifer
321 Sharpe Potter, PhD, MPH, Penney Cowan, Chad D Kollas, MD, FACP, FAAHPM, Danial Laird,
322 MD, JD, Barby Ingle, J Julian Grove, MD, Marian Wilson, PhD, MPH, RN-BC, Kshelle
323 Lockman, PharmD, MA, Fiona Hodson, RN, DipAPPSci, Carol S Palackdharry, MD, MS, FACP,
324 Roger B Fillingim, PhD, Jeffrey Fudin, PharmD, DAIPM, FCCP, FASH, FFSMB, Jennifer
325 Barnhouse, Ajay Manhapra, MD, Steven R Henson, MD, Bruce Singer, PhD, Marie Ljosenvoor,
326 PharmD, Marlisa Griffith, RN, Jason N Doctor, PhD, Kimeron Hardin, PhD, ABPP, FACHP,
327 Cathleen London, MD, Jon Mankowski, CA, LCSW, Andrea Anderson, Linda Ellsworth, FNP-C,
328 Lisa Davis Budzinski, Becky Brandt, RN, Greg Hartley, PT, DPT, Debbie Nickels Heck, MD,
329 Mark J Zobrosky, Celeste Cheek, PT, DPT, Megan Wilson, Cynthia E Laux, RN, Geralyn Datz,
330 PhD, Justin Dunaway, PT, DPT, Eileen Schonfeld, RN, Chaplain, Melissa Cady, DO, Thérèse
331 LeDantec-Boswell, Meredith Craigie, MD, FFPMANZCA, FANZCA, John Sturgeon, PhD,
332 Pamela Flood, MD, Melita Giummarra, PhD, Jessica Whelan, MSN, FPMHNP-BC, Beverly E
333 Thorn, PhD, Richard L Martin, Michael E Schatman, PhD, Maurice D Gregory, MD, Joshua Kirz,
334 PhD, Patti Robinson, PhD, James G Marx, MD, FASAM, Jessica R Stewart, Phillip S Keck,
335 PhD, LCP, Scott E Hadland, MD, MPH, MS, Jennifer L Murphy, PhD, Mark A Lumley, PhD,
336 Kathleen S Brown, PhD, Michael S Leong, MD, Mechele Fillman, MSN, NP, James W Broatch,
337 MSW, Aaron Perez, PT, Kristine Watford, MD, Kari Kruska, RN (Retired), Dokyoung Sophia
338 You, PhD, RN, Stacy Ogbeide, PsyD, MS, ABPP, Amy Kukucka, MSN, APRN, CHPN, FNP-C,
339 Susan Lawson, PhD, LCSW, James B Ray, PharmD, CPE, T Wade Martin, MD, James B
340 Lakehomer, PhD, Anne Burke, MPsy (clin), Dip Clin Hyp, Robert I Cohen, MD, MA, Peter
341 Grinspoon, MD, Marc S Rubenstein, PT, DPT, Cert-APHPT, Stephani Sutherland, PhD
342 (Neuroscience), Kristie Walters, RN (Retired), Travis Lovejoy, PhD, MPH,
343 “International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on
344 Forced Opioid Tapering,” Pain Medicine, Volume 20, Issue 3, March 2019, Pages 429–
345 433, <https://doi.org/10.1093/pm/psy228>

346
347 **16.** Walmart Inc., Plaintiff, v. U.S. Department of Justice; Attorney General William P. Barr;
348 U.S. Drug Enforcement Administration; Acting Administrator Timothy J. Shea, Defendants. Case
349 4:20-cv-00817 Document 1 Filed 10/22/20. [https://corporate.walmart.com/media-](https://corporate.walmart.com/media-library/document/walmart-v-doj-dea-complaint/_proxyDocument?id=00000175-522e-dbe2-a9fd-7f6e94120000)
350 [library/document/walmart-v-doj-dea-complaint/_](https://corporate.walmart.com/media-library/document/walmart-v-doj-dea-complaint/_proxyDocument?id=00000175-522e-dbe2-a9fd-7f6e94120000)
351 [proxyDocument?id=00000175-522e-dbe2-a9fd-](https://corporate.walmart.com/media-library/document/walmart-v-doj-dea-complaint/_proxyDocument?id=00000175-522e-dbe2-a9fd-7f6e94120000)
[7f6e94120000](https://corporate.walmart.com/media-library/document/walmart-v-doj-dea-complaint/_proxyDocument?id=00000175-522e-dbe2-a9fd-7f6e94120000)

- 352
- 353 **17.** Manchikanti, L., Kaye, A. M., Knezevic, N. N., McAnally, H., Slavin, K., Trescot, A. M.,
354 Blank, S., Pampati, V., Abdi, S., Grider, J. S., Kaye, A. D., Manchikanti, K. N., Cordner, H.,
355 Gharibo, C. G., Harned, M. E., Albers, S. L., Atluri, S., Aydin, S. M., Bakshi, S., & Barkin, R. L.
356 (2017). Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain:
357 American Society of Interventional Pain Physicians (ASIPP) Guidelines. *Pain Physician*, 20(2S),
358 S3–S92. <https://pubmed.ncbi.nlm.nih.gov/28226332/>
359
- 360 **18.** Guzman, A. (n.d.). The Opioid Epidemic and the Practice of Medicine:p.12,13.
361 https://www.deadiversion.usdoj.gov/mtgs/pract_awareness/conf_2019/dec_2019/guzman.pdf
362
- 363 **19.** Tracking FY2019 Federal Funding to Combat the Opioid Crisis | Bipartisan Policy
364 Center. (n.d.). [Bipartisanpolicy.org. https://bipartisanpolicy.org/report/combating-the-opioid-](https://bipartisanpolicy.org/report/combating-the-opioid-crisis-2020/)
365 [crisis-2020/](https://bipartisanpolicy.org/report/combating-the-opioid-crisis-2020/)
366
- 367 **20.** Commission on Combating Synthetic Opioid Trafficking. Commission on Combating
368 Synthetic Opioid Trafficking: Final Report. Reports from the Commission on Combating
369 Synthetic Opioid Trafficking (2022). Published online February 8, 2022. p.9
370 https://www.rand.org/pubs/external_publications/EP68838.html.
- 371 **21.** Peppin, J. F., & Coleman, J. J. (2021). CDC's Efforts to Quantify Prescription Opioid
372 Overdose Deaths Fall Short. *Pain and therapy*, 10(1), 25–38. [https://doi.org/10.1007/s40122-](https://doi.org/10.1007/s40122-021-00254-z)
373 [021-00254-z](https://doi.org/10.1007/s40122-021-00254-z)
374
- 375 **22.** Seth, P., Rudd, R. A., Noonan, R. K., & Haegerich, T. M. (2018). Quantifying the
376 Epidemic of Prescription Opioid Overdose Deaths. *American journal of public health*, 108(4),
377 500–502. <https://doi.org/10.2105/AJPH.2017.304265>
378
- 379 **23.** (2021). Drugabuse.gov.
380 https://www.drugabuse.gov/sites/default/files/Overdose_data_1999-2019.xlsx
381
- 382 **24.** Underlying Cause of Death, 1999-2019 Request. Cdc.gov. Published 2017.
383 <https://wonder.cdc.gov/ucd-icd10.html>
384

- 385 **25.** Treatment Episode Data Set (TEDS) 2000 -2010 National Admissions to Substance
386 Abuse Treatment Services. (n.d.). Retrieved December 17, 2021, from
387 [https://www.samhsa.gov/data/sites/default/files/2010_Treatment_Episode_Data_Set_National/2](https://www.samhsa.gov/data/sites/default/files/2010_Treatment_Episode_Data_Set_National/2010_Treatment_Episode_Data_Set_National.pdf)
388 [010_Treatment_Episode_Data_Set_National.pdf](https://www.samhsa.gov/data/sites/default/files/2010_Treatment_Episode_Data_Set_National/2010_Treatment_Episode_Data_Set_National.pdf)
389
- 390 **26.** 2018 TEDS Annual Report. www.samhsa.gov. Accessed December 17, 2021.
391 [https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html#](https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html#PSU)
392 [PSU](https://www.samhsa.gov/data/sites/default/files/reports/rpt31097/2018_TEDS/2018_TEDS.html#PSU).
393
- 394 **27.** ANNUAL SURVEILLANCE REPORT OF DRUG-RELATED RISKS AND OUTCOMES.
395 (2019). <https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf>
396
- 397 **28.** MME per capita U.S. 2014-2018 | Statista. (n.d.). Statista.
398 <https://www.statista.com/statistics/753284/number-of-mme-dispensed-per-capita-in-us/>
399
- 400 **29.** Prescription Opioid Trends in the United States. www.iqvia.com.
401 [https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-](https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states)
402 [states](https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states)
403
- 404 **30.** U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center. (2021, June
405 23). [Www.cdc.gov](http://www.cdc.gov). <https://www.cdc.gov/drugoverdose/rxrate-maps/index.html>
406
- 407 **31.** Prevalence and Profile of High Impact Chronic Pain.” NCCIH.
408 [https://www.nccih.nih.gov/research/research-results/prevalence-and-profile-of-high-](https://www.nccih.nih.gov/research/research-results/prevalence-and-profile-of-high-impact-chronic-pain)
409 [impact-chronic-pain](https://www.nccih.nih.gov/research/research-results/prevalence-and-profile-of-high-impact-chronic-pain)
410
- 411 **32.** Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-
412 Impact Chronic Pain Among Adults — United States, 2016. *MMWR Morbidity and*
413 *Mortality Weekly Report*. 2018;67(36):1001-1006.
414 DOI: [http://dx.doi.org/10.15585/mmwr.mm6736a2external icon](http://dx.doi.org/10.15585/mmwr.mm6736a2external%20icon)
415
416
417

418

Table A1: Summary of Regression Models Fit in the Paper

Dependent Variable	Independent Variable	Years	Related Figure	n	R ²	P-Value	Slope	95% LCL	95%UCL	Interpretation
MME per Capita	Total Annual Prescription Opioid Sales	2006-2010	NA	5	0.94	0.006	141	76	206	Strong Model. Significant, Positive Relationship.
Total Overdose Deaths	MME per Capita	2006-2010	NA	5	0.97	0.002	20	14	26	Strong Model. Significant, Positive Relationship.
Any Opioid Overdose Deaths	MME per Capita	2006-2010	NA	5	0.99	0.000	20	17	24	Strong Model. Significant, Positive Relationship.
Prescription Opioid Deaths	MME per Capita	2006-2010	NA	5	0.97	0.002	15	10	20	Strong Model. Significant, Positive Relationship.
Opioid Treatment Admissions/1000	MME per Capita	2006-2010	NA	5	0.91	0.011	0.60	0.26	0.94	Strong Model. Significant, Positive Relationship.
Total Overdose Deaths	MME per Capita	2010-2019	Figure 3	10	0.89	0.000	-85	-109	-61	Strong Model. Significant, Negative Relationship.
Any Opioid Overdose Deaths	MME per Capita	2010-2019	Figure 3	10	0.92	0.000	-76	-95	-57	Strong Model. Significant, Negative Relationship.
Prescription Opioid Deaths	MME per Capita	2010-2019	Figure 3	10	0.03	0.615	-1.4	-7.4	4.7	No Model. Nonsignificant Relationship.
Opioid Treatment Admissions/1000	MME per Capita	2010-2018	Figure 3	9	0.89	0.000	-0.64	-0.84	-0.43	Strong Model. Significant, Negative Relationship.

419

420

421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440


Captions for Figures

Figure 1: CDC Chart 1999-2010, February 28, 2018, Congressional testimony “Combatting the Opioid Crisis.” made before the Committee on Energy & Commerce, Subcommittee on Health U.S. House of Representatives: “The CDC has shown that a sharp increase in prescriptions for opioids resulted in a corresponding rise in addiction and overdose deaths. This is a CDC graph. The green line represents opioid prescribing, the red line represents opioid deaths, and the blue line represents opioid addiction. The green line went up as opioid prescriptions started to soar, it led to parallel increases in addiction and overdose deaths.”⁷

Figure 2: 2010-2019 Update: The green line represents opioid prescribing (POS, MME/capita); the red lines are opioid deaths (POD, AOD & TOD); the blue line represents opioid addiction (OTA). Over the past decade, as the green line (prescription opioids) declined by +50%, prescription opioid deaths remained flat while opioid addiction, any opioid and total overdose deaths continued increasing “exponentially”⁸.

Figure 3: 2010-2019 Regression Models: Illustrates the regression of OTA, POD, AOD and TOD as functions of POS. Significant, negative relationships were found for OTA, AOD, and TOD. No significant relationship exists between POD and POS.


441 **Figure 1**



Source: CDC

442


443 **Figure 2**



444

445

446 **Figure 3**



447

448

449